

Decision 13-D-21 of December 18, 2013

Decision 13-D-21 of 18 December 2013
regarding practices implemented on the
French market for high-dosage
Buprenorphine sold in private practices

Posted on: December 19, 2013 | Sector(s) :

PRESS / MEDIA

Presentation of the decision

Information about the decision

Origin of the case

Arrow Génériques

Company(ies) involved

Schering-Plough, Financière MSD, Merck & Co, Reckitt Benckiser Healthcare (UK) Ltd, Reckitt Benckiser plc

Read

Full text of the Opinion

4.74 MB

Press release